NBL-028
CLDN6-expressing advanced tumors (testicular, ovarian, NSCLC, endometrial cancer)
Phase 1Active
Key Facts
Indication
CLDN6-expressing advanced tumors (testicular, ovarian, NSCLC, endometrial cancer)
Phase
Phase 1
Status
Active
Company
About NovaRock Biotherapeutics
NovaRock Biotherapeutics is a private, preclinical-to-clinical stage biotech focused on next-generation antibody therapies for oncology and autoimmunity. The company's lead asset, NBL-028, a CLDN6-CD137 bispecific T cell engager, has received FDA IND clearance to enter Phase 1 trials, marking a significant milestone. NovaRock's proprietary NovaTE platform is designed to create conditionally active T cell engagers with improved safety profiles for solid tumors, positioning the company in a competitive but high-potential therapeutic space.
View full company profile